Empagliflozin/Metformin Extended-Release Tablets 25/1000 mg
Empagliflozin 25mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Dae Won Pharmaceutical Co., Ltd.
MFDS item code 202500781 · Approved 2025.04.03
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps control blood sugar in adults with type 2 diabetes when used in conjunction with diet and exercise. It is particularly effective in patients whose blood sugar is not well controlled, and caution is required when there is pre-existing cardiovascular disease. This medication improves blood sugar control, aiding in the treatment of diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole and not split, crushed, ground, or chewed. For patients taking this medicine because adequate glycemic control cannot be achieved with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's existing metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other symptoms that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication is used for the treatment of type 2 diabetes and helps to control blood sugar levels. However, it can rarely cause a serious condition known as lactic acidosis. Lactic acidosis can lead to excessive accumulation of lactic acid in the body, which can be a dangerous state; therefore, if symptoms appear, you should consult a doctor immediately. In addition, there is a risk of hypoglycemia if taken together with insulin or sulfonylureas, so caution is advised. This medication should not be used in patients with severely impaired kidney function or acute renal injury. It should be discontinued for a certain period before and after surgery, and resumed only after kidney function has returned to normal. This medication should also be avoided or used with caution in cases of severe infections, dehydration, heart failure, or hepatic dysfunction. It should be discontinued for a period before and after any tests using iodinated contrast media to minimize the risk of kidney injury and lactic acidosis. This medication can increase the risk of genital infections and urinary tract infections, so immediate treatment should be received if any symptoms of infection appear. During use, vitamin B12 levels may decrease, so it is advisable to check regularly through blood tests. Alcohol can increase the risk of side effects, so it is important not to overindulge while taking this medication. It is preferable not to use this medication in pregnant or potentially pregnant women, as well as in breastfeeding women. Elderly patients or those with weak kidney function should have their dosages adjusted and kidney function assessed regularly. This medication should be swallowed whole without breaking or chewing the tablets, and while the coating may be excreted in stool, this is normal. In cases of overdose, the risk is more towards lactic acidosis than toxicity, and appropriate treatment should be received in a hospital. Finally, this medication should be stored out of the reach of children and kept in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container, avoiding exposure to air or moisture, and kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps to maintain its effectiveness and ensure safe use.
Dark orange oval extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Dae Won Pharmaceutical Co., Ltd.
Empagliflozin 10mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg · Empagliflozin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg · Empagliflozin 12.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Metformin Hydrochloride with Colloidal Anhydrous Silica 757.5mg · Empagliflozin 5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg · Empagliflozin 12.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.